Arcutis Biotherapeutics (ARQT) EBIAT (2020 - 2025)
Arcutis Biotherapeutics (ARQT) has 6 years of EBIAT data on record, last reported at $17.4 million in Q4 2025.
- For Q4 2025, EBIAT rose 261.24% year-over-year to $17.4 million; the TTM value through Dec 2025 reached -$16.1 million, up 88.47%, while the annual FY2025 figure was -$16.1 million, 88.47% up from the prior year.
- EBIAT reached $17.4 million in Q4 2025 per ARQT's latest filing, up from $7.4 million in the prior quarter.
- Across five years, EBIAT topped out at $17.4 million in Q4 2025 and bottomed at -$107.7 million in Q3 2022.
- Average EBIAT over 5 years is -$46.8 million, with a median of -$48.5 million recorded in 2023.
- Peak YoY movement for EBIAT: crashed 109.48% in 2021, then soared 261.24% in 2025.
- A 5-year view of EBIAT shows it stood at -$71.3 million in 2021, then decreased by 0.97% to -$72.0 million in 2022, then grew by 7.96% to -$66.3 million in 2023, then soared by 83.72% to -$10.8 million in 2024, then skyrocketed by 261.24% to $17.4 million in 2025.
- Per Business Quant database, its latest 3 readings for EBIAT were $17.4 million in Q4 2025, $7.4 million in Q3 2025, and -$15.9 million in Q2 2025.